**Supplemental Table 1.** Proportion of subjects attending each study visit by BoNT-A formulation

| **Study visit** | **IncobotulinumtoxinA****N = 465** | **OnabotulinumtoxinA****N = 142** | **AbobotulinumtoxinA****N = 80** | **Study population****N = 701** |
| --- | --- | --- | --- | --- |
| Visit 1, n (%)a | 456 (98.1) | 140 (98.6) | 79 (98.8) | 685 (97.7) |
| Visit 2, n (%) | 386 (83.0) | 111 (78.2) | 64 (80.0) | 567 (80.9) |
| Visit 3, n (%) | 331 (71.2) | 91 (64.1) | 50 (62.5) | 477 (68.0) |
| Visit 4, n (%) | 276 (59.4) | 70 (49.3) | 35 (43.8) | 386 (55.1) |
| Visit 5, n (%) | 234 (50.3) | 47 (33.1) | 24 (30.0) | 309 (44.1) |
| Visit 6, n (%) | 207 (44.5) | 31 (21.8) | 20 (25.0) | 261 (37.2) |
| Visit 7, n (%) | 177 (38.1) | 20 (14.1) | 15 (18.8) | 214 (30.5) |
| Visit 8, n (%) | 151 (32.5) | 13 (9.2) | 13 (16.3) | 178 (25.4) |
| Final visit,b n (%) | 153 (32.9) | 24 (16.9) | 17 (21.3) | 196 (28.0) |

aTotal column includes subjects with a recorded injection, but for whom the BoNT-A formulation administered at the first injection was not reported; bthe final visit occurred at the end of the study, subjects did not receive an injection at this point and only those who returned for assessment were included in the analysis

Percentages based on total subject populations

BoNT-A – botulinum neurotoxin type A; n – number of observations; N – total number of subjects